2023
SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis
Barbayianni I, Kanellopoulou P, Fanidis D, Nastos D, Ntouskou E, Galaris A, Harokopos V, Hatzis P, Tsitoura E, Homer R, Kaminski N, Antoniou K, Crestani B, Tzouvelekis A, Aidinis V. SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis. Nature Communications 2023, 14: 5882. PMID: 37735172, PMCID: PMC10514346, DOI: 10.1038/s41467-023-41614-x.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisExtracellular matrix invasionLung fibroblastsIdiopathic pulmonary fibrosis patientsIdiopathic pulmonary fibrosisPulmonary fibrosis patientsMatrix invasionPromising therapeutic optionProfibrotic milieuTherapeutic optionsLung tissuePathogenic hallmarkPharmacological targetingFibrosisFibrosis patientsIncurable diseaseEx vivoBleomycinExtracellular matrix componentsTks5 expressionAberrant depositionInvasionMiceFibroblastsSrc kinase
2021
Prediction of Survival after Chronic Lung Allograft Dysfunction in Lung Transplant Recipients by Blood Profiling Using a Predefined 52 Gene Signature
Luijk B, Krebber M, Li Q, Kardol-Hoefnagel T, Budding K, van Kessel D, Grutters J, Otten H, Kaminski N, Maya J. Prediction of Survival after Chronic Lung Allograft Dysfunction in Lung Transplant Recipients by Blood Profiling Using a Predefined 52 Gene Signature. The Journal Of Heart And Lung Transplantation 2021, 40: s155-s156. DOI: 10.1016/j.healun.2021.01.470.Peer-Reviewed Original ResearchChronic lung allograft dysfunctionDiagnosis of CLADPeripheral blood mononuclear cellsLung allograft dysfunctionAllograft dysfunctionLTx recipientsRisk groupsHigh riskRisk scoreIdiopathic pulmonary fibrosis patientsLung transplant recipientsHigh-risk patientsKaplan-Meier analysisPulmonary fibrosis patientsBlood mononuclear cellsHigh-risk groupLow-risk groupLow-risk scoresPrediction of survivalLong-term survivalCLAD onsetCLAD patientsLung transplantationTransplant recipientsOverall survival
2018
S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension
Tzouvelekis A, Herazo‐Maya J, Ryu C, Chu J, Zhang Y, Gibson KF, Adonteng‐Boateng P, Li Q, Pan H, Cherry B, Ahmad F, Ford HJ, Herzog EL, Kaminski N, Fares WH. S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology 2018, 23: 771-779. PMID: 29611244, PMCID: PMC6047907, DOI: 10.1111/resp.13302.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPH patientsPH cohortCardiac outputWorld Health Organization group 1Idiopathic pulmonary fibrosis patientsPulmonary hypertension patientsPulmonary fibrosis patientsBlood mononuclear cellsProtein serum concentrationsHigher S100A12Pulmonary hypertensionS100A12 levelsOverall mortalityHypertension patientsPrognostic valueValidation cohortMononuclear cellsPeripheral bloodSerum concentrationsInflammatory diseasesGroup 1PatientsFibrosis patientsS100A12
2013
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal 2013, 43: 1430-8. PMID: 24177001, DOI: 10.1183/09031936.00141013.Peer-Reviewed Original ResearchConceptsIPF disease progressionDisease progressionIdiopathic pulmonary fibrosis patientsCarbon monoxide diffusion capacityPulmonary fibrosis patientsDisease progression eventsGAP subjectsIPF studiesPathological stromaVital capacityLOXL2 levelsProgression eventsDiffusion capacityFibrosis patientsSpirometric dataDisease severityPhysiological surrogatesProgressionPatientsRiskMultiple limitationsSubjectsLevelsProteomic analysisCohortPlasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, Otterbein L, Soejima M, Levesque MC, Gibson KF, Kaminski N, Pilewski JM, Donahoe M, Sciurba FC, Duncan SR. Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients. The Journal Of Immunology 2013, 191: 2089-2095. PMID: 23872052, PMCID: PMC3804013, DOI: 10.4049/jimmunol.1203476.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisB cellsIPF patientsIPF subjectsLung diseaseChronic obstructive pulmonary disease subjectsIdiopathic pulmonary fibrosis patientsPatient lung volumePulmonary artery pressureB cell aggregatesRestrictive lung diseasePulmonary fibrosis patientsB lymphocyte stimulatorB cell survivalArtery pressureIPF pathogenesisB cell differentiationIPF lungsNonspecific therapyBLyS levelsPulmonary fibrosisComplement depositionLung volumeLymphocyte stimulatorPatient outcomes
2011
Decreased Survival Of Idiopathic Pulmonary Fibrosis Patients With Heat Shock Protein 70 Autoreactivity
Xue J, Kahloon R, Bhargava A, Banga G, Gochuico B, Dacic S, Gibson K, Kaminski N, Sciurba F, Rosas I, Otterbein L, Zhang Y, Duncan S. Decreased Survival Of Idiopathic Pulmonary Fibrosis Patients With Heat Shock Protein 70 Autoreactivity. 2011, a4275-a4275. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4275.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosis patientsPulmonary fibrosis patientsDecreased survivalFibrosis patientsAutoreactivityPatients